Geoffrey Littlejohn

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum appears in Br J Rheumatol 1998 Oct;37(10):1142]

C J Hawkey, André Kahan, Klaus Steinbrück et al. · Lara D. Veeken · 1998 · 259 citations · Full text

Gastrointestinal Pharmacology, Gastroenterology, Pharmacotherapy +18

Pressure pain threshold in pain‐free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome

G. Granges, Geoffrey Littlejohn · Arthritis & Rheumatism · 1993 · 258 citations

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX- inhibiting Therapies (SELECT) trial in osteoarthritis

J. Dequeker, Christopher J. Hawkey, André Kahan et al. · Lara D. Veeken · 1998 · 225 citations · Full text

Efficacy Large-scale Evaluation, Gastrointestinal Pharmacology, Pharmacotherapy +18

A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease.

A. J. Barnett, M H Miller, Geoffrey Littlejohn · PubMed · 1988 · 169 citations

Rheumatology, Type 1, Early Stages +13

Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids.

Y. Kipen, Rachelle Buchbinder, Andrew Forbes et al. · PubMed · 1997 · 102 citations